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ImagingCell-penetrating peptides (CPPs) constitute a family of peptides with the characteristic ability to cross
biological membranes and deliver cargo into the intracellular milieu. Several CPPs have been proposed for
delivery of polypeptides and proteins into cells through either of two strategies: covalent or complexed in a
non-covalent fashion. Members of the PEP family are primary amphipathic peptides which have been shown
to deliver peptides and proteins into a wide variety of cells through formation of non-covalent complexes.
CADY is a secondary amphipathic peptide which has been demonstrated to deliver short nucleic acids, in
particular siRNA with high efﬁciency. Here we review the characteristics of the PEP and CADY carriers and
describe a novel derivative of CADY termed CADY2, which also presents sequence similarities to Pep1. We
have compared Pep1, CADY and CADY2 in their efﬁciency to interact with and internalize short ﬂuorogenic
peptides and proteins into cultured cells, and provide evidence that CADY2 can interact with proteins and
peptides and deliver them efﬁciently into living cells, similar to Pep1, but in contrast to CADY which is unable
to deliver any peptide, even short negatively charged peptides. This is the ﬁrst study to investigate the
inﬂuence of the cargo on the interactions between PEP and CADY carriers, thereby providing novel insights
into the physicochemical parameters underlying interactions and cellular uptake of peptides and proteins by
these non-covalent CPPs.S, ﬂuorescence-activated cell
r localization sequence; PTD,
acid; mRFP, monomeric red
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ris).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction: features andapplicationsof cell-penetratingpeptides
Penetrating into the human body to explore its functions and treat
pathologies from the inside has always been part of human dreams, as
related in a number of science ﬁction novels such as Isaac Asimov's
“Fantastic Voyage”, describing the adventures of a miniaturized
submarine's journey through the human body [1]. Reality is a little
different since the plasma membrane constitutes an effective barrier
to penetration of many if not most biomolecules. Breaching the cell
membrane to reach an intracellular target indeed constitutes a
challenging experience. More often than not molecules presenting
potential for therapeutic intervention are limited by the lack of
permeability and high selectivity of the cell membrane, and
consequently never make it to the clinic due to poor delivery and
low bioavailability. Several alternatives have been devised to facilitate
the introduction of molecules which are refractory to cellular uptake,
including physical, chemical or biological strategies such as microin-jection, electropermeabilisation, viral transformation or non-viral
technologies such as facilitated delivery by so-called “smart drug
carriers” [2–7]. In order to develop highly efﬁcient strategies for the
controlled delivery of bioactive macromolecules with therapeutic
potential it is essential that the integrity and stability of the bioactive
molecule itself be preserved, whilst ensuring it reaches its intracel-
lular target. To this aim, several non-viral strategies have been
developed, including lipids, polycationic, carbon nanotubes and
nanoparticles, as well as peptide-based formulations, in particular
protein transduction domains (PTDs) and cell-penetrating peptides
(CPPs) [4–11].
The concept of protein transduction ﬁrst emerged from the ﬁnding
that transcription factors such as Antennaepedia homeodomain
protein and human immunodeﬁciency virus transactivating regula-
tory protein Tat shuttled between subcellular compartments and cells
[12,13], which gave rise to the ﬁrst PTDs: the third alpha helix of
Antennapedia homeobox [14] and the transactivating regulatory
domain of Tat [15–18]. Likewise several natural and synthetic peptide
sequences were found to penetrate and cross biological membranes
together with cargo macromolecules and therefore termed Cell-
Penetrating Peptides [7–9,19–27]. Over the last 20 years, the unique
properties of PTDs and CPPs have been exploited to deliver a wide
variety of biomolecules, including nucleic acids, peptides, proteins
and synthetic drugs into living cells and more recently in vivo, for the
delivery of therapeutic macromolecules (peptides, proteins, PNA,
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applied to treat hyperproliferative diseases such as cancer, asthma,
ischemia, stimulating cytotoxic immunity and diabetes [5–11,23–39].
Both covalent and non-covalent strategies based on PTDs/CPPs
have been developed, the former involving chemical linkage,
conjugation or genetic fusion to the cargo, the latter involving
formation of stable yet non-covalent complexes between carrier and
cargo. The covalent strategy is best exempliﬁed by TAT, the regulatory
transactivating domain of HIV [10,15,17,18], the third alpha helix of
Antennapaedia homeodomain protein, also known as Penetratin
[14,32], Transportan [22,40,41], calcitonin-derived peptides [42–44],
Herpes simplex viral protein VP22 [45] and polyarginine peptides
[20,21], antimicrobial peptides [46,47] and polyproline sweet arrow
peptide [48]. The ﬁrst non-covalent CPP, published in 1997, was the
short amphipathic peptide MPG shown to promote efﬁcient delivery
of nucleic acids into living cells, and more recently in vivo [49–52].
This approach was then extended to the design of Pep-1 in 2001, for
delivery of proteins and peptides [53], followed by the Pep-2 and Pep-
3 derivatives [54,55]. The success of these approaches lead to themore
recent design of a secondary amphipathic peptide named CADYwhich
has proven most efﬁcient for delivery of siRNA into challenging cell
lines and in vivo [56].
Herewe review the properties of PEP carriers andCADYanddescribe
a novel CPP, termed CADY2, which presents sequence similarities to
both CADY and Pep1. We have compared Pep1, CADY and CADY2 in
their efﬁciency to interact with and internalize short ﬂuorogenicFig. 1. Primary sequence and structure of PEP and CADY peptides. a) The primary sequence o
with a schematic representation of the Trp-rich domain in red, the positively charged, hyd
sequence of secondary amphipathic peptides CADY and CADY2 is shown together with a sche
in blue. c) Pymol 3D representation of the alpha helical fold of PEP and CADY peptides, Trppeptides and proteins into cultured cells. We provide evidence that
CADY2 can interact with proteins and short peptides and deliver them
efﬁciently into living cells, similar to Pep1. In contrast CADY is unable to
promote cellular uptake of any peptide, even short, hydrophobic and/or
negatively charged. Our ﬁndings provide novel insights into the
physicochemical parameters underlying interactions and delivery of
peptides and proteins into living cells by non-covalent CPPs of the PEP
and CADY families.
2. Primary amphipathic PEP carriers: delivery of proteins, peptides
and PNAs
Cell-penetrating peptide carriers of the PEP family are primary
amphipathic peptides consisting of a hydrophobic N-terminal domain
corresponding to a tryptophan-rich cluster (KETWWETWWTEW) and
a hydrophilic, lysine-rich C-terminal domain derived from the NLS of
SV40 large T antigen (KKKRKV), separated by a short linker (SQP)
which preserves the ﬂexibility and integrity of the two ﬂanking
domains, and is crucial for efﬁcient macromolecule delivery [53–55]
(Fig. 1). The N-terminal domain is required for both efﬁcient targeting
to the cell membrane and hydrophobic interactions with the cargo,
whilst the C-terminal domain is involved in electrostatic interactions
with the cargo and intracellular routing to the nucleus. It should be
noted that N-terminal acetylation and addition of a C-terminal
cysteamide are essential for efﬁcient cellular uptake and stabilization
of Pep/cargo complexes [57,58]. Pep carriers can mediate cellularf primary amphipathic peptides of the PEP family: Pep1, Pep2, Pep3 is shown, together
rophilic domain in blue, and negatively charged amino acids in green. b) The primary
matic representation of Trp and Phe residues in red, and positively charged Arg residues
and Phe residues in red, Arg residues in blue, and Glu residues in green.
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nucleic acid analogues with a peptide backbone, such as Peptide
Nucleic Acids (PNAs) with high efﬁciency through formation of non-
covalent complexes with their cargo. These CPPs present several
advantages including rapid delivery of cargo into cells with very high
efﬁciency, stability in physiological buffers, lack of toxicity and of
sensitivity to serum. Moreover, unlike covalent CPPs, Pep carriers
enter cells independently of the endosomal pathway, therefore
allowing for controlled release of the cargo into the cytoplasm
where it is free to reach its target subcellular compartment. Pep-based
technologies constitute excellent alternatives to covalent strategies
and powerful tools for protein and peptide applications both ex vivo
and in vivo. Moreover they hold a strong promise for therapeutic
applications and formulations have been optimized for systemic
intravenous, intratumoral and intratracheal injection into mouse
models, as well as for sprays for nasal delivery and topical
administration [7–9,36,59–61].
The ﬁrst Pep carrier, Pep1 (Ac-KETWWETWWTEWSQPKKKRKV-
Cya), originally developed for protein transduction, provided the ﬁrst
proof-of-concept for non-covalentdeliveryof peptides andproteins into
culturedmammalian cells. This 21-residue carrier was indeed shown to
mediate efﬁcient delivery of a variety of peptides and proteins,
independently of their nature and size, including 120–150 kDa proteins
such as beta-galactosidase and antibodies in their fully biologically
active form, into a large panel of cell types, including non-transformed,
transformed and cancer-derived cell lines, challenging primary, neuro-
nal and pancreatic cell lines, hepatocytes, macrophages, and human
stem cells [36,53]. Moreover Pep-1 has been applied to the delivery of
proteins into mouse models, to produce alveolar wall apoptosis in the
lung, to correct defects in protein kinase A function, and to deliver
proteins across the blood brain barrier [59–61]. Pep-1 presents high
nanomolar afﬁnity for most proteins and peptides, and associates
rapidly with them through both non-covalent electrostatic and
hydrophobic interactions which appear to be favoured by tryptophan
residues. Aside frompeptides and proteins, Pep-1has been documented
to interact with a wide variety of cargo including quantum dots and
uncharged hydrophobic molecules [36,62]. Pep-1 forms stable non-
covalent complexes with the cargo and the Pep-1/cargo ratio has been
shown to be critical for efﬁcient delivery and associated biological
response. For most proteins and peptides optimal complex formation is
achieved for a Pep-1/cargo molar ratio of 20/1. Light scattering
experiments and electron microscopy have provided concording
evidence that biologically active Pep-1/cargo complexes form homo-
geneous nanoparticles (100–200 nm diameter) [63] The use of higher
ratios generally leads to precipitation or to the formation of larger
particles or aggregates that are rather poorly taken up by cells and tend
to accumulate the cell surface or within endosomes. Pep1 appears to be
extremely versatile from a structural point of view, and can adopt
different conformations which are both dependent on the environment
and the cargo. Moreover, it has been reported to interact strongly with
membrane lipids, and can spontaneously insert into membranes. The
mechanismof Pep-1membrane transductionwas characterized in vitro
through associationof several biophysical approaches, and itwas shownTable 1
Peptide sequences of PEP and CADY variants. Primary amphipathic PEP peptides and seco
features. All of these cell-penetrating peptides are acetylated at their N-terminus and bear
complex stabilization.
Name Size MW pI
Pep1 Ac-KETWWETWWTEWSQPKKKRKV-Cy 21mer 2848 9
Pep2 Ac-KETWFETWFTEWSQPKKKRKV-Cy 21mer 2770 9
Pep3 Ac-KWFETWFTEWPKKRK-Cy 15mer 2097 10
CADY1 Ac-GLWRALWRLLRSLWRLLWRA-Cy 20mer 2650 12
CADY2 Ac-GLWWRLWWRLRSWFRLWFRA-Cy 20mer 2906 12that Pep1 undergoes a conformational rearrangement upon interaction
with lipids, and that its insertion into themembrane is accompanied by
membrane disorganization and transient pore formation allowing for
transient ionic currents [57,64,65].
The Pep-2 variant (Ac-KETWFETWFTEWSQPKKKRKV-Cya) was
optimized for the delivery of DNAmimics, by substituting Trp residues
at positions 5 and 9 in the hydrophobic Trp-rich motif of Pep-1 by two
Phe groups (Fig. 1, Table 1) [54]. Pep-2 interacts with uncharged PNAs
and derivatives including HyPNA-pPNAs and facilitates their cellular
uptake [54]. Fine characterization of Pep-2 thanks to a series of
mutant and deletion variants showed that the position of the TrpPhe
tandems are critical for cellular uptake of this peptide carrier. Pep-2
was employed to target proteins which are essential for several
signalling pathways in living cells, and was more recently optimized
for in vivo applications, through design of the 15-mer derivative, Pep-
3 (Ac-KWFETWFTEWPKKRK-Cya) (Fig. 1, Table 1) [55]. Pep-3 bears
the minimal sequence required for interactions with both PNAs and
HypNA-pPNA analogues, and membrane lipids, thereby forming
stable carrier complexes for efﬁcient cellular uptake of both PNAs
and HypNA-pPNAs. Pep-3 was successfully applied to delivery of
HypNA-pPNA targeting the mitotic cyclin B1, thereby yielding a
speciﬁc antisense response with efﬁciency similar to that of low
nanomolar concentrations of siRNA, providing a potent means of
delivering these molecules into suspension and primary cell lines, and
of inhibiting tumour growth following intratumoral injection in a
mouse tumour model [55]. Moreover, Finally N-terminal PEGylation
of Pep-3 was shown to improve the stability of Pep-3/HypNA-pPNA
particles in vivo, following intravenous injection, thereby leading to a
4–5 fold more efﬁcient inhibition of tumour growth [55]. Hence Pep-3
constitutes one of the few CPPs which is successfully applicable in vivo
for delivery of DNAmimicswith a peptide backbone, such as antisense
PNA at submicromolar concentrations.
3. The secondary amphipathic carrier CADY: delivery of siRNA
CADY (Ac-GLWRALWRLLRSLWRLLWRA-Cya) is a secondary amphi-
pathic peptideof20 residuesderived fromthechimerical peptide carrier
PPTG1, a variant of the JTS1 fusion peptide, previously reported to
interact with nucleic acids but not with short oligonucleotides
[56,66,67] (Fig. 1, Table 1). CADY bears four Trp groups and ﬁve Arg
which are evenly distributed throughout its sequence, but nonegatively
charged residues, thereby constituting a highly positively charged and
fairly hydrophobic peptide (20% aromatic; 25% positively). CADY is
further modiﬁed by N-terminal acetylation and a C-terminal cystea-
mide, which stabilizes complexes with the cargo and improves cellular
uptake. LikePEP carriers, CADY interacts stronglywithmembrane lipids,
and spontaneously penetrates and inserts intomembranes. In fact CADY
has been shown to adopt a helical conformation in model membranes,
Trp groups forming a hydrophobic interface distinct from charged
residues on (helical representation in Fig. 1b; see also [56]), which
facilitates cellular uptake. CADYassociates rapidly andwith high afﬁnity
(nanomolar range), with small oligonucleotides and siRNA but not DNA
plasmids, therebyyielding stable yet non-covalent complexeswhich arendary amphipathic CADY peptides are presented together with their physicochemical
a C-terminal cysteamide, both of which are required for efﬁcient cellular uptake and
W F %WF K R %KR D %E
.82 5 0 23.8 5 1 28.6 3 14.3
.82 3 2 23.8 5 1 28.6 3 14.3
3 2 23.8 4 1 33.3 2 13.3
.6 4 0 20 0 5 25 0 0
.6 6 2 40 0 5 25 0 0
Fig. 2. Pep1-mediated delivery of proteins and peptides affecting cell cycle progression.
a) Pep1/p27Kip complexes formed at different molar ratios from 1/1 to 50/1 (0.5 μg
p27Kip protein in 100 μl PBS) were overlaid onto HS68 ﬁbroblasts synchronized by
serum starvation and incubated for 24 h. The distribution of cells throughout the cell
cycle was determined by ﬂow cytometry, and the percentage of cells arrested in G1 (2N
DNA content) was reported as a function of the molar ratio of Pep1/p27. b) Pep1 was
complexed with 10–7 M FITC-labelled MP51 peptide at a 20/1 molar ratio and overlaid
onto HS68 ﬁbroblasts for 1 h. c) Asynchronous HS68 ﬁbroblasts grown to subcon-
ﬂuency were treated with DMEM (1), with 10–6 M Pep-1 (2) 10–7 MMP51 alone (3) or
different concentrations of Pep1/MP51 complexed at a 20/1 molar ratio (4–6) for 24 h
and processed for FACS analysis (ﬁxed and stained with propidium iodide).
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and primary cell lines [56]. Although CADY/siRNA interactions are
essentially driven by electrostatic interactions, involving Arg residues,
they also involve contacts with the Trp residues, which further play a
critical role in stabilizing complexes and facilitating their insertion into
the membrane. CADY-mediated delivery of subnanomolar concentra-
tions of siRNA leads to signiﬁcant knockdown of the target gene at both
the mRNA and protein levels. Moreover CADY is not toxic and enters
cells through a mechanism which is independent of the major
endosomal pathway. Given its biological properties, it has been
proposed that CADY-based technology could have a signiﬁcant effect
on the development of fundamental and therapeutic siRNA-based
applications.
We designed a new cell-penetrating peptide termed CADY2 (Ac-
GLWWRLWWRLRSWFRLWFRA-Cya) which is derived from the
secondary amphipathic sequence of CADY, and harbours two TrpTrp
and two TrpPhe tandems, as found in Pep1 and Pep2, respectively, ﬁve
Arg groups, but no negative charges, thereby constituting a highly
hydrophobic and positively charged peptide (40% aromatic/25%
positively charged) (Fig. 1, Table 1). Since CADY2 bears similar
sequence features to both CADY and PEP carriers, we asked whether it
might share functional properties with its parental counterparts or
present distinctive characteristics, in particular with respect to
delivery of peptide and protein cargo, thereby also providing
information on the physicochemical parameters underlying carrier/
cargo interactions and sequence requirements for cellular uptake.
4. Comparison of Pep1, CADY and CADY2-mediated delivery of
peptides and proteins
4.1. Pep1-mediated delivery of peptides and proteins affecting cell cycle
progression
Pep1 has been shown to mediate efﬁcient internalization of
proteins and peptides into living cells, and to yield a robust biological
response upon introduction of cargo tampering with cell cycle
progression. As shown in Fig. 2a, Pep-1-mediated delivery of the
27 kDa and inhibitor of cyclin-dependent kinases p27Kip is sufﬁcient
to block cell cycle progression of human ﬁbroblasts in G1, with a most
efﬁcient biological response with formulations at 15/1–25/1 molar
ratio Pep1/p27Kip [63]. This strategy is of particular relevance for
cancer therapy, since the function of this tumour suppressor protein is
frequently affected in tumour cells, and its restoration has been
shown to constitute a promising anticancer approach [68]. A similar
strategy was applied to block cell cycle progression at the G2/M
transition through delivery of a 51mer peptide, MP51 (MEFSLKD-
QEAKVSRSGLYRSPSMPENLNRPRLKQ-VEKFKDNTIPDKVKKKC), de-
rived from the interface between human Cdc25C phosphatase and
cyclin B1 [69]. Cdc25 phosphatases play a central role in cell cycle
progression and checkpoint signalling through activating dephos-
phorylation of cyclin-dependent kinases. Moreover these phospha-
tases are associated with cancer, which makes them attractive targets
for drug development [70,71]. The structural and biochemical features
of MP51 were previously characterized in vitro and shown to interact
speciﬁcally and with high afﬁnity with both cyclin B and 14-3-3 in
vitro and in extracto [69]. MP51 was therefore complexed with Pep1
and delivered into HS68 human ﬁbroblasts, accumulating in large part
in the nucleus (Fig. 2b). Moreover, whereas treatment of cells with
medium (DMEM), Pep1 or MP51 alone had no signiﬁcant effect on cell
cycle progression, Pep1/MP51 complexes induced accumulation of
cells with a 4 N DNA content, indicating that Pep-1-mediated delivery
of MP51 effectively prevented cells from progressing beyond mitosis
(Fig. 2c). Interestingly, submicromolar concentrations of Pep1/MP51
were less efﬁcient than nanomolar concentrations. This effect could be
associated with partial aggregation of high concentrations of com-
plexes within the cell membranes.4.2. CADY2 interacts with and promotes efﬁcient delivery of proteins into
HeLa cells
Since Pep1 has been shown to deliver a wide variety proteins into
cultured cells, it was used to compare binding and delivery efﬁciency
of CADY and CADY2. We chose to characterize the binding properties
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biology studies, the monomeric form of the Red Fluorescent Protein
(mRFP), an autoﬂuorescent 29 kDa protein with an isoelectric point of
5.68 (13 aromatic residues, 34 positively charged and 43 negatively
charged amino acids) (Fig. 3a). Titration with Pep1 lead to signiﬁcant
quenching of mRFP ﬂuorescence (26% at saturation) and curve ﬁtting
yields a dissociation constant value of 288 nM+/−144 nM, indicative
of a stable interaction. Likewise, titration ofmRFPwithCADY2promoted
ﬂuorescence quenching of mRFP (46%) and curve ﬁtting yielded a
dissociation constant value of 73 nM+/−29 nM. In contrast titration of
mRFP with CADY does not affect mRFP ﬂuorescence, suggesting that it
does not interact with this protein Fig. 3b. To verify whether these
interactions were biologically relevant, mRFP was complexed at 1 μM
with each of the three carriers at 20/1, 30/1 or 40/1 molar ratio and
overlaid onto HeLa cells. In agreement with their binding ability, both
Pep1 and CADY2 internalized mRFP efﬁciently at all ratios, whereas
CADY was unable to deliver mRFP, irrespective of the ratio applied to
form complexes, leading to accumulation of ﬂuorescent aggregates at
the surface of cell membranes, as shown in Fig. 3c. Similar experiments
were performed with a ﬂuorescently-labelled form of GST-Cdk2, a
34 kDa protein, with an isoelectric point of 7.67 (33 aromatic residues,
66 positively charged and 67 negatively charged amino acids), which
yielded essentially the same results,with dissociation constant values ofFig. 3. Pep1 and CADY2 interact with and transduce mRFP. a) 200 nM mRFP were titrated
monitored by ﬂuorimetry at 620 nm following excitation at 584 nm. b) Titration of 200 nMm
(panels A–C), CADY (panels D–F) or CADY2 (panels G–I) at 40/1 molar ratio (lower ratio
extensively washed with PBS, stained with Hoechst, ﬁxed and observed by wide-ﬁeld epiﬂuo
with Hoechst; panels C, F, I: overlay.194 nM+/−104 nM and 55 nM+/−18 nM for CADY2 and Pep1,
respectively. Taken together, these results infer that CADY is unable to
interact with and deliver proteins into cultured cells in stark contrast
with CADY2 and Pep1. Moreover in vitro CADY2 presents a 3.5–3 fold
higher afﬁnity for protein cargo than Pep1, although does not have any
signiﬁcant impact on cellular uptake.4.3. CADY cannotmediate cellular uptake of ﬂuorescently-labelled peptides
We next characterized the ability of Pep1, CADY and CADY2 to
interact with a variety of peptides ranging from 8mers to 33mers, with
different isoelectric points and variable compositions in aromatic,
hydrophobic and charged amino acids (Table 2), in an attempt to
establish a rationale for the interactions of each of the carriers with
different cargo as a function of their physicochemical features. To this
aim, cargopeptideswere labelledwith FITCon their unique cysteine and
titrated with Pep1, CADY and CADY2. As summarized in Table 3, these
experiments allowed to determine dissociation constant values to
compare the afﬁnity of interactions of each carrier for each peptide.
Moreover carrier/cargo complexeswere formed at 20/1, 30/1 and 40/1
molar ratio, and overlaid onto cultured HeLa cells to evaluate their
transduction efﬁciency.with increasing concentrations of Pep1 or CADY2 and changes in ﬂuorescence were
RFP with CADY, as described in a). c) Complexes formed between 1 μMmRFP and Pep1
s were less efﬁcient) were overlaid onto HeLa cells for 1 h at 37 °C. Cells were then
rescence microscopy. Panels A, D, G: mRFP ﬂuorescence; panels B, E, H: nuclear staining
Table 2
Sequence and properties of cargo peptides used in this study. The cargo peptides used in this studywere all derived from cell cycle proteins which have previously been characterized
in our group and which are involved in critical protein/protein interactions with protein partners. A: acidic peptides, N: neutral peptides (6.5bpIb7.5), B: basic peptides. A20K3 is
derived from alpha helix of ubiquitin, B20F from alpha helix of Sumo [73]. N28, A33 and B20FY are derived from the N-terminus, the alpha1-insertion-alpha2 helix, and the alpha
helix 3 of Yeast Cks1, respectively [73]. B8 is derived from a consensus substrate sequence of cyclin-dependent kinases [74]. A18 is derived from the PSTAIRE helix of CDK2 [75]. A14,
N14, B14W and B8Y are all derived from CDK1. B14, A20, A24 and MP51 [69] are all derived from human Cdc25C.
Name Sequence Size MW W F Y K R D E pI Hydroph
B8 HHASPRKC 8mer 935 0 0 0 1 1 0 0 9.51 −0.50
B8Y GVPVRTYC 8mer 894 0 0 1 0 1 0 0 8.22 +0.09
A14 CVSLQDVLMQDSRL 14mer 1607 0 0 0 0 1 2 0 4.21 −0.01
B14 SANLSILSGGTPKC 14mer 1347.5 0 0 0 1 0 0 0 7.94 +0.19
B14W CWKPGSLASHVKNL 14mer 1540 1 0 0 2 0 0 0 9.3 +0.07
N14 CVKLLDVIHTENKL 14mer 1625 0 0 0 2 0 1 1 6.74 +0.08
A18 TEGCPSTAIREISLLKEL 18mer 1960 0 0 0 1 1 0 3 4.78 +0.04
A20 CLDLSNLSSGEITATQLTTS 20mer 2054 0 0 0 0 0 1 1 3.67 +0.14
A20K3 VESSDTIDNVKSKIQDKEGC 20mer 2195 0 0 0 3 0 3 2 4.44 −0.32
B20F IKKTTPLRRLMEAFAKRQGC 20mer 2348 0 1 0 3 3 0 1 11.01 −0.32
B20FY LFKRPLNYEAELRAATAAAC 20mer 2208 0 1 1 1 2 0 2 8.2 −0.01
A24 GEDQAEEISDELMEFSLKDQEAKV 24mer 2740.9 0 0 1 2 0 3 6 3.84 −0.17
N28 MYHHYHAFQGRKLTDQERARVLEFQDSC 28mer 3467 0 2 2 1 3 2 2 6.81 −0.27
A33 MLPKAMLKVIPSDYFNSEVGTLRILTEDEWRGC 33mer 3813 1 1 1 2 2 2 3 4.94 +0.05
MP51 See text 51mer 5995.9 0 2 1 9 4 3 4 9.84 −0.38
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signiﬁcant quenching of probe ﬂuorescence, and curve ﬁtting yielded a
wide range of dissociation constant values from 75 nM+/−12 nM for
N28 to 3633+/−446 nM for A20K3 (Fig. 4a, Table 3). Yet CADY did not
deliver any cargo peptide into cultured cells successfully, irrespective of
the molar ratio used for complex formation and ﬂuorescent aggregates
were found toaccumulate at the surfaceof cellmembranes, as shown for
B8Y in Fig. 4b, A14, A20K3, B20FY and N28 in Fig. 6. To further
understand why this quenching of ﬂuorescently-labelled peptides
observed upon titration with CADY did not correlate with any
internalization, we veriﬁed whether the probe itself might interact
with CADY, and found that this was indeed the case, with a dissociation
constant value of 346+/−113 nM (Fig. 4a). This indicates that CADY
interacts directly with FITC probe most likely through hydrophobic
contacts, and that certain residues within the cargo peptide may affect
the afﬁnity of the interaction and probe ﬂuorescence, although this is
insufﬁcient to promote cellular uptake of the peptide cargo.
In contrast, when we characterized the interactions between the
different peptide cargo labelled with FITC, Pep1 and CADY2, we found
they could be subdivided into three different groups: (1) the ﬁrst
presenting signiﬁcant enhancement of ﬂuorescence upon titrationwith
CADY2 or Pep1: B8, B8Y, B14, B14W, N14, A14, A18, A20 and B20FY;Table 3
Summary of dissociation constant values for interactions with peptide cargo. 200 nM cargo pe
buffer at pH7.2, 150 mMNaCl and changes inﬂuorescenceweremonitored and reported as a fu
Software (Erathicus Ltd.) and a standard quadratic equation, as described previously [72]. ENH
Cargo Pep1 CADY
Kd (nM) Fluo variation (%) Kd (nM)
FITC ND ND 346±113
B8 958±445 ENH 22% 134±99
B8Y 354±156 ENH 29% 191±93
A14 549±187 ENH 93% 2513±1140
B14 725±454 ENH 95% 408±223
B14W 648±200 ENH 45% No binding
N14 544±101 ENH 225% 2711±911
A18 609±124 ENH 140% 963±297
A20 1115±317 ENH 70% 575±141
A20K3 4±9 QUE 16% 3633±446
B20F 1038±189 ENH 45% No binding
B20FY 2582±1295 ENH 142% 1116±311
A24 117±31 QUE 25% 1011±272
N28 No binding None 75±12
A33 No binding None 406±61
mRFP 288±144 QUE 26% No binding
GST-Cdk2 194±104 QUE 25% No bindingB20F ﬂuorescence is enhanced upon titrationwith Pep1, not CADY2 (2)
the second associated with quenching of ﬂuorescence upon titration
with CADY2 or Pep1, exempliﬁed by A20K3 and A24, two highly
negatively charged peptides (3) the third characterized by a lack of
signiﬁcant variation of ﬂuorescence, as exempliﬁed by N28, A33 and
B20F for CADY2, indicative of a lack of interaction (see Table 3 and
Figs. 4–6).
4.4. CADY2 and Pep1 bind and mediate cellular uptake of a peptide cargo:
contribution of aromatic and charged residues
To gain insight into parameters underlying carrier/cargo interac-
tions and cellular uptake efﬁcacy, we addressed the impact of aromatic/
hydrophobic residues and of charged amino acids by comparing
peptides with different combinations of aromatic, positively charged
and negatively charged residues (see Tables 2 and 3, Figs. 4–6).
We ﬁrst characterized the interactions of Pep1, CADY and CADY2
with two short peptides of 8 residues, B8 and B8Y (FITC-labelled).
Neither of these peptide cargo bears any negatively charged residues;
B8 bears two positively charged residues, but no aromatic groups,
whilst B8Y bears 1 Tyr and 1 Arg. As described above, titration of
these peptideswith CADY leads to ﬂuorescence quenching associatedptides labelled with FITC were titrated with Pep1, CADY or CADY2 potassium phosphate
nction of CPP concentration. Data analysis and curve ﬁttingwas performed using theGraﬁt
: enhancement; QUE: quenching; ND: non determined.
CADY2
Fluo variation (%) Kd (nM) Fluo variation (%)
QUE 68% ND ND
QUE 17% 230±62 ENH 36%
QUE 27% 1046±532 ENH 76%
QUE 100% 663±343 ENH 63%
QUE 27% 446±151 ENH 137%
None 368±123 ENH 46%
QUE 58% 1372±914 ENH 123%
QUE 70% 372±201 ENH 91%
QUE 78% 205±222 ENH 13%
QUE 71% 4±10 QUE 14%
None No binding None
QUE 45% 112±56 ENH 14%
QUE 22% 340±126 QUE 19%
QUE 74% No binding None
QUE 89% No binding None
None 73±29 QUE 46%
None 55±18 QUE 20%
Fig. 4. Pep1 and CADY2, not CADY interact with and transduce ﬂuorescent peptides. a) 200 nM FITC and FITC-labelled peptides were titratedwith increasing concentrations of CADY and
changes inﬂuorescenceweremonitoredbyﬂuorimetry at 520 nmfollowing excitation at 495 nm. b)3 μMFITC-labelledB8Ywas complexedwith CADYat20/1 (panels A–C), 30/1 (panels
D–F) and 40/1 (panels G–I)molar ratios and overlaid ontoHeLa cells for 1 h at 37 °C. Cellswereprocessed for observation as described in Fig. 3b. PanelsA, D, G: FITCﬂuorescence; panels B,
E, H: nuclear stainingwithHoechst; panels C, F, I: overlay. c) 200 nM FITC-labelled B8Y and B8were titratedwith increasing concentrations of Pep1 and CADY2 as described in a). d) 3 μM
Cy3-labelled B8Ywas complexedwith Pep1 (panels A–C) CADY (panels D–F) or CADY2 (G–I) at 40/1molar ratio (lower ratioswere less efﬁcient) overlaid onto HeLa cells for 1 h at 37 °C
and processed for observation as described above. Panels A, D, G: Cy3 ﬂuorescence; panels B, E, H: nuclear staining with Hoechst; panels C, F, I: overlay.
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induced ﬂuorescence enhancement, and curve ﬁtting revealed that
CADY2 preferentially bound B8, whereas Pep1 displayed greater
afﬁnity for B8Y, with dissociation constant values of 230+/−62 nM
and 1046+/−532 nM for CADY2/ B8 and CADY2/ B8Y, and 958+/
−445 nM and 354+/−156 nM, respectively for Pep1/B8 and Pep1/
B8Y (Fig. 4c, Table 3). These short peptide cargoes were then labelled
with Cy3, complexed with Pep1, CADY or CADY2 at different molar
ratios and overlaid onto HeLa cells. As shown in Fig. 4d, CADY was
unable to deliver either of these short peptides into cells (in
agreement with data shown in Fig. 4b, thereby ruling out inefﬁcient
delivery associated with the nature of the probe). In contrast both
Pep1 and CADY2 promoted efﬁcient cellular uptake of these peptides,
although Pep1 was less efﬁcient than CADY2 in delivering B8 (data
not shown), whereas CADY was not very efﬁcient in delivering B8Y
below 40/1 molar ratio, in agreement with the low afﬁnities
observed for these carrier/cargo pairs in vitro. Taken together
these data indicate that both Pep1 and CADY2 can interact with
and deliver short cargo peptides into cultured cells, however Pep1
seems to favour peptides with an aromatic group, in contrast to
CADY2. Moreover these results indicate that the lack of negatively
charged residueswithin the peptide cargo does not prevent CADY2 or
Pep1 binding and cellular uptake.
Like B8, A14, B14, N14, A18, A20 and A20K3 all lack aromatic
residues. Fluorescence titration experiments revealed that all of
these peptides, exhibited a signiﬁcant increase in ﬂuorescence upon
titration with both CADY2 and Pep1, except for A20K3 whoseﬂuorescence underwent quenching (Fig. 5a and c). As found for B8,
the lack of aromatic residues in these cargo, correlated with a higher
afﬁnity for CADY2 than for Pep1, (except for A14 and N14), which
was especially obvious for A20, and to a lesser extent for B14 and A18
(Table 3). Like B8, B14 bears one positive charge, but no negatively
charged amino acids. Conversely, A20 does not bear any positively
charged amino acids. A14 and N14 harbour both positively and
negatively charged groups and present better binding afﬁnity for
Pep1, indicating that in the absence of aromatic groups, Pep1 may be
an overall better carrier when the cargo bears a balance of charges.
Moreover, these cargowere efﬁciently delivered into HeLa cells upon
complex formation with either Pep1 or CADY2, as exempliﬁed for
A14 (Fig. 6a).
The 20mer peptide A20K3 displayed particularly high afﬁnity for
both Pep1 and CADY2.With ﬁve negatively charged amino acids (25%),
counterbalanced by three positively charged groups (15%) this peptide
exhibited a completely different behaviour from the other peptides,
which was further accompanied by efﬁcient cellular uptake of this
peptide by both Pep1 and CADY2 (Figs. 5c and 6b). These data infer that
peptides with high charge density bind particularly well with either
carrier. Like A20K3, the 24mer A24 is characterized by a large excess of
negative charges (9 amino acids, 37%), accompanied by the presence of
both positively charged amino acids (2 amino acids, 8.3%) and one
aromatic group. Titration of A24 with Pep1 and CADY2 revealed a
behaviour similar to A20K3, characterized by quenching of probe
ﬂuorescence and high binding afﬁnity (Fig. 5c). In contrast to A20K3,
however, A24 displays higher afﬁnity for Pep1 than for CADY2, which is
Fig. 5. Cargo-dependent interactions with Pep1 and CADY2. 200 nM FITC-labelled peptides were titrated with increasing concentrations of Pep1 and CADY2 and changes in
ﬂuorescence were monitored by ﬂuorimetry at 520 nm following excitation at 495 nm. a) B14, A20, A14, B14W, A18 and B20FY. b) B20F, N28 and A33. c) A20K3 and A24.
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observed for B8Y.
B8Y, B14W, B20F, A24, B20FY, N28 and A33 all bear one or more
aromatic residues. Fluorescence titration experiments show that all of
these peptides, except for N28, A33 and B20Fwith CADY2, are subject to
variations in the ﬂuorescence of the associated probe upon titration
with Pep1 and CADY2, indicative of carrier/cargo interactions, further
associated with cellular uptake, as exempliﬁed for B20FY (Figs. 5a and
6c, Table 3). Peptides B14W and B20FY displayed preferential binding
for CADY2. The 20mer B20F did not bind either CADY or CADY2, and
bound Pep1 with micromolar afﬁnity. This peptide harbours a large
proportion of positively charged amino acids with respect to negatively
charged groups (6+ for 1−), which is most likely detrimental to its
interactionwith CADY2 (Fig. 5b). The longer peptides N28 (28mer) and
A33 (33mer) both bear hydrophobic residues and a similar balanced
charge distribution, although A33 is more acidic than N28 (isoelectric
point of 4.94 and 6.81, respectively). Titration of these peptides with
either Pep1 or CADY2 did not promote any changes in ﬂuorescencewhich could be attributable to an interaction (Fig. 5b). In agreement
with these data, when N28 and A33 were complexed with Pep1, CADY
or CADY2 at molar ratios ranging from 20/1 to 40/1, and overlaid onto
HeLa cells, neither condition leads to successful internalization (Fig. 6d).
We propose that the conformational features of longer peptides may be
responsible for this lack of interaction, since Pep1 and CADY2 can
mediate cellular uptake of short acidic peptides such as A14 and A20K3,
and Pep1 can promote efﬁcient delivery of the 51mer peptide MP51.
Table 4 summarizes the major cargo preferences of Pep1, CADY2 and
CADY.
5. Materials and methods
5.1. Peptide synthesis and labelling
Peptides were synthesized by solid-phase peptide synthesis using
AEDI-expensin resin with (ﬂuorenylmethoxy)-carbonyl (Fmoc) con-
tinuous (Pionner, Applied Biosystems, Foster city, CA) as described
Fig. 6. Cellular uptake by Pep1, CADY and CADY2. a) 1 μM FITC-labelled A14 b) A20K3 c) B20FY and d) N28 were complexed with Pep1 (panels A–C) CADY2 (panels D–F) or CADY
(panels G–I) at 40/1 molar ratio and overlaid onto HeLa cells for 1 h at 37 °C (lower ratios were less efﬁcient). Cells were processed for observation as described in Fig. 4. Panels A, D,
G: FITC ﬂuorescence; panels B, E, H: nuclear staining with Hoechst; panels C, F, I: overlay.
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reverse-phase high performance liquid chromatography (RP-HPLC;
C18 column Interchrom UP5WOD/25 M Uptisphere 300 5 ODB, 250Table 4
Summary of cargo preferences for Pep1 and CADY2. Major cargo preferences are presented
CPP High afﬁnity interactions: efﬁcient cellular uptake
PEP1 Aromatic residues not required (A20K3, N14, A14, B14, B8)
For 14–24mer peptides, lacking aromatic groups, preference for highly
charged peptides with a balance of positive and negative charges: 4–6
charged residues (A20K3NN14NA14)
Excess of negative charges over positive charges results in high afﬁnity
binding and efﬁcient uptake (A20K3, A24)
The presence of aromatic groups improves binding of poorly charged
peptides (B8YNB8; B14WNB14) and favours binding to Pep1 over CADY2
(A24, B20F)
CADY2 Aromatic residues not required (A20K3, A20, A18, A14, B14, B8)
For short peptides, charged residues preferred over aromatic groups (B8NB8Y)
Low negative charge (A20) or positive charge alone (B8, B14) is sufﬁcient
for binding and efﬁcient uptake
For 20–24mer peptides, preference for highly charged peptides
(A20K3, B20FY, A24)
4 fold greater afﬁnity than Pep1 for proteins
CADY Interaction with FITC probe
Afﬁnity of interaction with labelled peptide N28NB8NB8YNFITC
Quenching of FITC probe increases together with acidity of the peptidemm×21.2 mm) and identiﬁed by electrospray mass spectrometry
and amino acid analysis. Fluorescently-labelled peptides were gener-
ated by chemical coupling of FITC onto a unique cysteine using a tenfoldfor the different peptide carriers.
Low afﬁnity or no binding: inefﬁcient or lack of uptake
Negative charges alone affect binding afﬁnity, although cellular uptake still
occurs (A20)
Excess of positive charges over negative charges detrimental to binding, but cellular
uptake still occurs (B20F and B20FY)
Long peptides with high charge and presence of aromatic groups (N28 and A33)
do not bind, inferring steric hindrance or repulsion related to secondary structure
Large excess of positive charges is detrimental to binding (B20F) (likely due to
repulsion with positive charges in CADY2)
Long peptides with high charge and the presence of aromatic groups (N28 and A33)
do not bind inferring parameters related to a secondary structure such as steric
hindrance
No cellular uptake for any peptide irrespective of size, isoelectric point, overall
charge and hydrophobicity
No binding and no cellular uptake of proteins
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from the free label on NAP-10 Sephadex columns (GE Healthcare) and
the concentration of labelled peptide was determined by measuring
absorbance at 495 nM.
5.2. Protein expression and puriﬁcation
His-tagged mRFP was expressed by IPTG induction overnight at
37 °C of BL21 transformed with pRSETB-mRFP [72]. mRFP was puriﬁed
by afﬁnity on His-Trap followed by gel ﬁltration on Superdex75.
5.3. Fluorescence spectroscopy titration experiments
200 nM ﬂuorescent protein or peptide were titrated with
increasing concentrations of Pep1, CADY or CADY2 in a 200 μl volume
potassium phosphate buffer at pH 7.2, 150 mM NaCl in 96-well
microplates and changes in ﬂuorescence were monitored at 25 °C
with a Polarstar spectroﬂuorimeter at 520 nm following excitation at
485 nm for FITC and at 620 nm following excitation at 584 nm for
mRFP. Data analysis and curve ﬁtting was performed using the Graﬁt
Software (Erathicus Ltd.) and a standard quadratic equation,
assuming a stoichimetric interaction between carrier and cargo
peptides, as described previously [73].
5.4. Cell culture, delivery and microscopy
HeLa cells were grown in DMEM supplementedwith glutamine, 10%
foetal calf serum, 1 mMpenicillin and 1 mM streptomycin at 37 °C in an
atmosphere containing 5% CO2. Peptide and protein complexes were
preformed essentially as described previously [52] by incubating carrier
and cargo at 1:20, 1:30 or 1:40 molar ratio in 100 μl PBS for 1 h at room
temperature prior to addition onto cultured cells. Internalization
experiments were performed by overlaying carrier/cargo complexes
onto cells cultured to subconﬂuency on glass coverslips, for 1 h at 37 °C.
For observation, cells were ﬁxed for 15 min with paraformaldehyde,
nuclei were stained with Hoechst 33342 (Sigma), and cells were
mounted with Prolong Gold AntiFade Reagent (Invitrogen). Epiﬂuores-
cence images were acquired on a Leica DMRIBO microscope (Leica
Microsystems) piloted by theMetamorph software (Universal Imaging),
and images were processed using ImageJ software.
5.5. Flow cytometry analysis of cell cycle progression
Cells were treated with trypsin–EDTA, harvested by centrifugation
and resuspended in a staining solution containing 0.1% Triton X-100, 5%
glycerol and 50 μg/ml Propidium Iodide (Sigma) for at least 30 min. The
cell cycle proﬁle of cellswas characterized byﬂuorescence-activated cell
sorting (FACS) on a BD FACScalibur ﬂow cytometer equipped with
CellQuest software.
6. Discussion
The ability of a small fraction of molecules to cross biological
membranes is inherent to their physicochemical properties and a ﬁne
balance between hydrophobicity, charge, size and structure. However
the majority of biomolecules cannot penetrate into cells, thereby
requiring some form of physical introduction or delivery to reach their
intracellular target. Over the past 20 years, several strategies have been
developed to enhance the uptake of biomolecules with therapeutic
potential, whilst preserving their functional integrity, thereby improv-
ing their efﬁcacy and bioavailability. In particular, cell-penetrating
peptides that form non-covalent complexes with their cargo have
proven a most efﬁcient means, and a powerful alternative to covalent
approaches for introducing biological macromolecules into living cells.
Pep1 is a fairly hydrophobic peptide that bears a total of 6 positively
charged residues for half as many negatively charged Asp groups. Assuch, Pep1 has been documented to interact with and deliver a large
variety peptides and proteins into cells [36,52]. With a complete lack of
negatively charged residues, 5 Arg and 4 Trp residues, CADY is a
positively charged and hydrophobic peptide, which is well suited for
interactions with negatively charged biomolecules, such as siRNA [55].
The interactions between these carriers and their cargo have been
reported to involve a combination of hydrophobic and electrostatic
contacts through aromatic and charged groups. In particular Trp
residues and TrpPhe tandems appear to play amajor role in stabilization
of the carrier/cargo complex and insertion into the membrane.
Moreover, the helical conformation of these CPPs, associated with
their amphipathic character, has been reported to be essential for their
interaction with the cell membrane and their overall function as a CPP.
We have designed a “chimeric” peptide, CADY2 which combines the
properties of both CADY and PEP carriers, thereby constituting a highly
hydrophobic peptide, with twice as many aromatic amino acids with
respect to CADY, due to additional Trp and Phe residues introduced to
mimic the TrpTrp and TrpPhe tandems of PEP carriers within the
peptide sequence derived from CADY.
Here we describe the features of the non-covalent cell-penetrating
peptides PEP and CADY, and compare the ability of Pep1, CADY and
CADY2 to interact with and deliver into living cells proteins and a panel
of peptides with different physicochemical properties (length, charge,
hydrophobicity and isoelectric point) as well as a novel variant termed
CADY2whichpresents similarphysicochemical properties tobothCADY
and Pep1. Given the highly positively charged nature of CADY and its
associated afﬁnity for negatively charged siRNA,wehypothesized that it
might interact with short, negatively charged peptides and promote
their cellular delivery. Howeverwe found that CADYwas unable to bind
and to deliver proteins or peptides into cells, even when peptide cargos
were short and negatively charged. In most cases, titration of
ﬂuorescently-labelled peptideswith CADYwas associatedwith a strong
quenching of probe ﬂuorescence, but this was not corroborated by the
CADY-mediated cellular uptake of peptide cargo, andwe found that this
was a consequence of direct interactions between CADY and the probe,
most likely through hydrophobic contacts, although the amino acid
composition of the cargo peptide affected the afﬁnity and extent of
ﬂuorescence variation.
In contrast, CADY2 presents high afﬁnity and an efﬁcacy at least as
great as that of Pep1 in delivering proteins such as mRFP and GST-
Cdk2 and a subset of peptides into living cells. We found obvious
differences in afﬁnity for different cargo, depending on their
physicochemical properties, and between Pep1 and CADY2 carriers
and a same cargo. Whilst the titration of some peptides with Pep1 or
CADY2, lead to enhancement of associated probe ﬂuorescence, others
yielded signiﬁcant ﬂuorescence quenching, and others yet were
completely unaffected, indicative of a lack of carrier/cargo interaction
which was associated with a lack of cellular uptake. In particular we
found that short peptides (8–24mer) with charged residues, whether
positive or negative, bound both CADY2 and Pep1, and that the
presence of an aromatic group in the peptide cargo was not necessary
binding to either carrier, but tended to promote higher afﬁnity for
Pep1 than for CADY2, and conversely, the lack of aromatic residues
within the peptide cargo favoured their interactions with CADY2.
Amongst the ﬁfteen different peptide cargoes that were tested, some
presented particularly high afﬁnity for both Pep1 and CADY2, and this
appeared to be essentially associated with a high proportion of both
positively and negatively charged residues within the cargo. Indeed,
an excess of positively charged residues was detrimental to interac-
tions with CADY2, most likely due to a strong charge repulsion. Finally
characterization of longer peptides (N25mer) with similar features to
shorter peptides, such as the presence of hydrophobic residues and a
balanced charge distribution, revealed that binding to Pep1 and
CADY2 implicated more complex rules, such as conformational
features which are likely to play a major role in carrier/cargo complex
formation, and consequently in cellular uptake.
2284 L. Kurzawa et al. / Biochimica et Biophysica Acta 1798 (2010) 2274–2285Non-covalent CPP technologies present several advantages for
delivery of peptides and proteins. Although they may still need to be
optimized for systematic in vivo applications, they are already proven
powerful tools for basic researchand for targeting speciﬁc cellular events
both in vitro and in vivo, as well as in a therapeutic context for screening
potential therapeuticmolecules. This is theﬁrst study of the inﬂuence of
the cargo on the interactions between CADY and PEP carriers. Our data
conﬁrm that Pep1 is an excellent carrier for most proteins and peptides,
but that CADY2 can equally serve to delivermany peptides into cultured
cells, in contrast to CADY, which is essentially unable to deliver short
peptides and proteins into cells. We provide evidence that several
parameters associated with the nature of peptide cargo are involved, in
particular the presence of aromatic and charged residues. Theseﬁndings
provide novel insights into the physicochemical parameters underlying
interactions and cellular uptake of peptides and proteins by non-
covalent CPPs of the PEP and CADY families. Understanding the features
underlying efﬁcient carrier/cargo binding associated with the nature of
the cargo will be important for the future design of biomolecules for
diagnostic or therapeutic purposes such as biosensors for the detection
and drugs for the inhibition of intracellular targets.
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